Av Canal Repair — Cost, Top Hospitals & Success Rates | MyMedicPlus

Atrioventricular (AV) canal repair — also known as atrioventricular septal defect (AVSD) repair — is open-heart surgery to correct a complex congenital heart malformation in which the central fibrous body of the heart fails to develop normally, resulting in a deficiency of both the atrial and ventricular septa and abnormal formation of the atrioventricular valves (mitral and tricuspid). The spectrum ranges from partial AVSD (primum atrial septal defect with a cleft in the anterior mitral leaflet only) to complete AVSD (large combined atrial and ventricular septal defect with a common atrioventricular valve — the AV canal or endocardial cushion defect).

Complete AVSD is found in approximately 40% of patients with Down syndrome (trisomy 21) and is the most common congenital heart defect in this population. Left untreated, complete AVSD causes progressive pulmonary arterial hypertension from left-to-right shunting at both atrial and ventricular levels, combined with AV valve regurgitation, leading to Eisenmenger syndrome and irreversible pulmonary vascular disease by 12–18 months of age. For this reason, surgical repair is recommended at 3–6 months of age before pulmonary hypertension becomes irreversible.

Repair is performed on cardiopulmonary bypass through a median sternotomy under moderate hypothermia. The central defect is closed using either a single patch technique or a two-patch technique (modified Rastelli), and the common AV valve is divided into separate left and right components with repair of the cleft in the left (mitral) valve leaflet to reduce post-repair regurgitation. The procedure carries excellent results at experienced congenital cardiac surgery centres.

Complete AVSD is the primary indication for AV canal repair, consisting of a combined primum atrial septal defect, inlet ventricular septal defect, and common AV valve. It causes bidirectional shunting with pulmonary overcirculation, volume overloading of both ventricles, and progressive mitral and tricuspid regurgitation. Symptoms in infancy include poor feeding, failure to thrive, tachypnoea, and recurrent respiratory infections. Echocardiography confirms the diagnosis with additional delineation of AV valve morphology (Rastelli type A, B, or C) which guides surgical approach.

Partial AVSD (primum ASD with cleft mitral valve, without an inlet VSD) is the milder form, with symptoms appearing in older childhood or adulthood — right heart volume overload, mitral regurgitation murmur, and atrial arrhythmias. Repair is still indicated when haemodynamically significant and is less complex than complete AVSD repair. Transitional AVSD represents an intermediate form. Associated cardiac anomalies including tetralogy of Fallot, pulmonary stenosis, and left ventricular outflow obstruction require additional surgical steps.

All infants with haemodynamically significant complete AVSD are candidates for elective surgical repair at 3–6 months of age, before the development of irreversible pulmonary vascular disease. Earlier operation (2–3 months) is required in infants failing to thrive despite medical management. Patients with Down syndrome — who have accelerated pulmonary hypertension development — require particularly timely referral to specialist congenital cardiac surgery centres.

Cardiac catheterisation with pulmonary vascular resistance assessment is required if repair is contemplated after 6–12 months of age, to ensure pulmonary vascular resistance is not prohibitively elevated (less than 8 Wood units indexed is the generally accepted threshold for operability). Repair is contraindicated in established Eisenmenger syndrome with irreversible pulmonary hypertension. Associated conditions such as severely hypoplastic left ventricle, unbalanced AVSD (markedly asymmetric ventricular sizes favouring one side), or functionally univentricular heart anatomy may require palliation with staged single-ventricle pathway (Norwood/Fontan) rather than biventricular repair.

The single-patch technique (modified Rastelli/Australian technique) uses a single Dacron or pericardial patch to close both the atrial and ventricular components of the defect simultaneously, with the AV valve leaflet tissue sandwiched between the patch and the crest of the ventricular septum. The two-patch technique places a separate ventricular patch (pericardium or Dacron) to close the VSD and a separate atrial patch to close the primum ASD, allowing more precise AV valve reconstruction. Both approaches achieve equivalent outcomes in experienced hands.

AV valve reconstruction — particularly repair of the cleft in the anterior left AV valve leaflet — is performed with interrupted sutures to restore leaflet coaptation and reduce mitral regurgitation. Preservation of as much subvalvar apparatus as possible and avoidance of significant residual mitral stenosis are key technical goals. Intraoperative transoesophageal echocardiography immediately after weaning from bypass is essential to assess repair quality — residual significant AV valve regurgitation or stenosis may require immediate revision before closing the chest. Balloon-tipped catheters placed in the coronary sinus allow selective cardioplegia delivery.

Selecting the most appropriate Av Canal Repair approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Complete AVSD repair at experienced centres achieves early operative mortality of less than 2–5% in uncomplicated cases, with 20-year survival rates exceeding 85% in patients with standard anatomy and complete repair. Post-operative resolution of pulmonary hypertension occurs in virtually all patients operated on before 6 months of age with pre-operative normal to mildly elevated pulmonary vascular resistance. Left AV valve function (mitral analogue) is the most critical determinant of long-term outcome — approximately 5–10% of patients require reoperation for significant mitral regurgitation within 10 years.

For patients with Down syndrome, surgical outcomes match those of chromosomally normal patients when trisomy 21 is the only additional risk factor; long-term neurodevelopmental outcomes are similar to non-operated Down syndrome peers of the same IQ and chromosomal complement. Repair in infancy prevents the development of Eisenmenger syndrome and enables normal growth, activity, and quality of life for these children.

Early post-operative risks include complete heart block (requiring permanent pacemaker in 1–2% of cases due to proximity of the repair suture line to the AV node), residual VSD, residual atrial septal defect, and left AV valve dysfunction requiring reoperation. Pulmonary hypertensive crises in the first 24–72 hours post-operatively are managed with inhaled nitric oxide, sedation, and pulmonary vasodilator therapy. Low cardiac output syndrome is managed with inotropic support and, rarely, mechanical circulatory support.

Medium and long-term risks include progressive left AV valve regurgitation (the most common late complication, requiring reoperation in 5–15% of patients by 10 years), left ventricular outflow obstruction (subaortic stenosis developing in 5–10% as the heart grows), and atrial arrhythmias including supraventricular tachycardia and atrial fibrillation. Long-term antibiotic endocarditis prophylaxis is recommended for the first 6 months after repair and thereafter if residual defects or prosthetic material remain.

Post-operative hospitalisation is typically 7–21 days depending on the complexity of repair and post-operative course. Chest drains are removed on post-operative days 1–3. Medications including diuretics and cardiac medications are weaned as pulmonary haemodynamics normalise. Most infants feed and gain weight normally within 2–4 weeks of a successful repair.

Long-term follow-up is essential at specialist congenital heart disease centres. Echocardiography at 6 weeks, 6 months, 1 year, and annually thereafter assesses AV valve function, left ventricular outflow tract gradient, and ventricular function. Cardiology review continues into adulthood, as adult congenital heart disease follow-up is necessary for life. Children with Down syndrome also require multidisciplinary developmental, educational, and therapeutic support independent of their cardiac care.

Complete AVSD repair in the United States at a paediatric cardiac surgery centre costs USD 80,000–150,000 inclusive of surgery, cardiopulmonary bypass, ICU care, and hospital stay. Paediatric congenital heart surgery costs in the UK's NHS are covered, but waiting times and access to specialist centres vary.

JCI-accredited paediatric cardiac surgery centres in India perform complete AVSD repair at approximately USD 8,000–15,000, in Thailand USD 15,000–25,000, and in Turkey USD 12,000–20,000 — savings of 75–90% compared to US pricing. Centres including Narayana Institute of Cardiac Sciences (Bangalore), Apollo Children's Hospital (Chennai), and Kokilaben Dhirubhai Ambani Hospital (Mumbai) have internationally trained paediatric cardiac surgeons with high-volume AVSD repair experience and outcomes published in peer-reviewed journals.

Several key factors determine the final cost of Av Canal Repair: clinical complexity of the individual case, the specific technique or protocol selected, specialist time required, imaging and laboratory testing, implant or device costs where applicable, and the duration of post-treatment monitoring. Geographic location exerts a strong influence — urban tertiary-care centres in high-income countries charge premium rates, while equivalent accredited care in India, Thailand, Turkey, and Mexico provides comparable clinical outcomes at 50–75% lower cost. Patients seeking international treatment should factor in travel, accommodation, and the cost of follow-up care on return home. Private health insurance coverage varies considerably; patients should obtain pre-authorisation in writing and confirm what components of the treatment pathway are included. Many patients access government healthcare subsidies or medical financing plans to spread the cost of elective and semi-elective procedures.

There is no effective medical alternative to surgical repair for haemodynamically significant AVSD. Medical management with diuretics (furosemide, spironolactone), ACE inhibitors, and caloric supplementation may stabilise infants with heart failure symptoms before definitive surgery but cannot arrest progression to pulmonary hypertension if repair is delayed beyond 6 months.

For patients with unbalanced AVSD (one ventricle too small for biventricular repair), staged single-ventricle palliation (pulmonary artery banding to restrict pulmonary blood flow as a first stage, followed by Glenn and Fontan procedures) represents the only surgical pathway, accepting a circulation without a true biventricular repair at the cost of lower long-term exercise tolerance and late complications of the Fontan circulation. Transcatheter techniques do not currently provide an alternative to surgical AVSD repair.